FY2024 EPS Estimates for Zealand Pharma A/S (OTCMKTS:ZLDPF) Increased by Analyst

Zealand Pharma A/S (OTCMKTS:ZLDPF) – Investment analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for Zealand Pharma A/S in a research note issued on Monday, July 22nd. Cantor Fitzgerald analyst P. Agrawal now expects that the company will post earnings of ($2.25) per share for the year, up from their previous forecast of ($2.53). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zealand Pharma A/S’s current full-year earnings is ($2.29) per share.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 16th. The company reported ($0.54) earnings per share for the quarter. The business had revenue of $2.20 million for the quarter. Zealand Pharma A/S had a negative return on equity of 36.96% and a negative net margin of 213.77%.

Zealand Pharma A/S Price Performance

ZLDPF stock opened at $135.66 on Wednesday. The business has a 50 day moving average price of $110.47 and a 200 day moving average price of $93.38. The stock has a market cap of $6.99 billion, a price-to-earnings ratio of -74.54 and a beta of 0.97. Zealand Pharma A/S has a fifty-two week low of $35.19 and a fifty-two week high of $140.28. The company has a quick ratio of 12.28, a current ratio of 12.30 and a debt-to-equity ratio of 0.10.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.